RESUMO
We compared the written responses of physicians (n=303) and patients (n=961) from a nationwide US survey concerning atopic dermatitis (AD). Physicians, primarily dermatologists, responded to 32 questions, and patients responded to 44 questions about AD and its management. Most physicians and patients were in agreement regarding disease severity, the relative lack of effectiveness of over-the-counter products, concerns about drug adverse effects, and the need for more patient support groups. However, physicians were more concerned about long-term adverse effects than were patients. Additionally, 91% of physicians versus 46% of patients rated prescription medications as "moderately" or "very" effective. Patients were generally pleased with their overall AD-related medical care: 42% were "a lot" or "very" satisfied, while only 8% were dissatisfied. Although physician and patient perceptions sometimes differed, both groups preferred treatments offering greater effectiveness, fewer adverse effects, and greater applicability to the pediatric population.
Assuntos
Atitude do Pessoal de Saúde , Dermatite Atópica/diagnóstico , Dermatite Atópica/tratamento farmacológico , Fármacos Dermatológicos/provisão & distribuição , Fármacos Dermatológicos/uso terapêutico , Satisfação do Paciente/estatística & dados numéricos , Médicos/estatística & dados numéricos , Adolescente , Adulto , Feminino , Pesquisas sobre Atenção à Saúde/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de DoençaRESUMO
The National Eczema Association for Science and Education surveyed 429 patients with atopic dermatitis or their parents and 303 physicians about atopic dermatitis, its effect on quality of life (QOL), and the adequacy of available treatments. The physician survey focused on disease severity and management; the patient survey, on disease severity, impact on QOL, and treatment preferences. Physician and patient/parent respondents generally agreed about their assessments of disease severity, poor effectiveness of over-the-counter products, and the need for more patient support groups and toll-free phone information. Atopic dermatitis significantly impacts QOL in children, particularly in those with moderate-to-severe disease. New treatments should offer enhanced efficacy, less frequent application, and fewer adverse effects.